Protein C activated - Kaketsuken/Teijin

Drug Profile

Protein C activated - Kaketsuken/Teijin

Alternative Names: Activated protein C - Kaketsuken/Teijin; Anact C; CTC-111

Latest Information Update: 21 Dec 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaketsuken; Teijin Pharma
  • Developer Teijin Pharma
  • Class Anticoagulants; Antithrombotics; Biological factors; Blood proteins; Enzyme precursors; Glycoproteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Disseminated intravascular coagulation

Highest Development Phases

  • Marketed Deep vein thrombosis; Disseminated intravascular coagulation; Pulmonary embolism

Most Recent Events

  • 31 Jul 2001 Launched for Pulmonary embolism in Japan (IV)
  • 31 Jul 2001 Launched for Disseminated intravascular coagulation in Japan (IV)
  • 31 Jul 2001 Launched for Thrombosis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top